The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Major findings and recent advances in virus–like particle (VLP)-based vaccines
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature Reviews Immunology · doi:10.1038/nri2868 · Cited by 2,106
Self-citationPeptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin
Zakeri, B., Fierer, J. O., Celik, E., Chittock, E. C., Schwarz-Linek, U., Moy, V. T., & Howarth, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115485109 · Cited by 1,662
Nanoparticles target distinct dendritic cell populations according to their size
Manolova, V., Flace, A., Bauer, M., Schwarz, K., Saudan, P., & Bachmann, M. F. (2008) · European Journal of Immunology · doi:10.1002/eji.200737984 · Cited by 1,289
Self-citationTherapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877
N-Linked Glycosylation in Campylobacter jejuni and Its Functional Transfer into E. coli
Wacker, M., Linton, D., Hitchen, P. G., Nita-Lazar, M., Haslam, S. M., North, S. J., Panico, M., Morris, H. R., Dell, A., Wren, B. W., et al. (2002) · Science · doi:10.1126/science.298.5599.1790 · Cited by 777
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Cited by
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Mucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
Multifunctional biomolecule nanostructures for cancer therapy
Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 488
DNA Vaccines—How Far From Clinical Use?
Hobernik, D., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113605 · Cited by 457
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
Nanoparticle-Based Vaccines Against Respiratory Viruses
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., & Archambault, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00022 · Cited by 299
Recent Advances in CRISPR/Cas9 Delivery Strategies
Yip, B. (2020) · Biomolecules · doi:10.3390/biom10060839 · Cited by 292
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Self-citationEngineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
Bruun, T. U. J., Andersson, A.-M. C., Draper, S. J., & Howarth, M. (2018) · ACS Nano · doi:10.1021/acsnano.8b02805 · Cited by 281
Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo
Kato, Y., Abbott, R. K., Freeman, B. L., Haupt, S., Groschel, B., Silva, M., Menis, S., Irvine, D. J., Schief, W. R., & Crotty, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.001 · Cited by 269
Delfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Recombinant vaccines for COVID-19
Yadav, T., Srivastava, N., Mishra, G., Dhama, K., Kumar, S., Puri, B., & Saxena, S. K. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1820808 · Cited by 105
Bahar, M. W., Porta, C., Fox, H., Macadam, A. J., Fry, E. E., & Stuart, D. I. (2021) · npj Vaccines · doi:10.1038/s41541-020-00267-3 · Cited by 42
Metadata
- Authors
- Mohsen, M. O., Zha, L., Cabral-Miranda, G., & Bachmann, M. F.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 34
- Pages
- 123-132
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W2753483322
- Cited by
- 555
- References
- 77
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.